Media coverage about Cellectar Biosciences (NASDAQ:CLRB) has been trending somewhat positive on Thursday, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cellectar Biosciences earned a daily sentiment score of 0.01 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 46.8480318763672 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Separately, Zacks Investment Research downgraded Cellectar Biosciences from a “hold” rating to a “sell” rating in a research report on Tuesday, November 21st.
Shares of Cellectar Biosciences (NASDAQ:CLRB) traded down $0.01 during trading on Thursday, hitting $1.36. The stock had a trading volume of 130,300 shares, compared to its average volume of 134,000. Cellectar Biosciences has a fifty-two week low of $1.08 and a fifty-two week high of $3.07. The stock has a market capitalization of $21.67, a P/E ratio of -1.27 and a beta of 0.97.
WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Cellectar Biosciences (CLRB) Stock Price” was published by Ticker Report and is the sole property of of Ticker Report. If you are reading this article on another publication, it was stolen and reposted in violation of United States & international copyright laws. The correct version of this article can be viewed at https://www.tickerreport.com/banking-finance/3125879/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-cellectar-biosciences-clrb-stock-price.html.
About Cellectar Biosciences
Cellectar Biosciences, Inc, formerly Novelos Therapeutics, Inc, is a clinical stage biopharmaceutical company. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. Its research and development program is based on its PDC cancer targeting delivery platform.
Receive News & Ratings for Cellectar Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectar Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.